Quality of life ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death Number of deaths over 36 months · stage III and IV cutaneous melanoma
1 finding from 1 review
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
Overall response rate (ORR), · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
Time to recurrence · stage III and IV cutaneous melanoma
1 finding from 1 review
Quality of life ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ( · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in overall survival ( compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
Progression‐free survival · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in progression‐free survival ( compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
EORTC QLQ‐C30 QoL at 6 months ‐ global health · women with advanced ovarian epithelial cancer
1 finding from 1 review
Overall survival (OS) · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, · stage III cutaneous melanoma
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).
1 finding from 1 review
Overall response rate (ORR), · stage III cutaneous melanoma
1 finding from 1 review